Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Oncology · Gallbladder and Extrahepatic Biliary Tract Carcinoma

What to Expect: Survivorship, Monitoring, and Ongoing Care

At a Glance

After surgery for gallbladder or biliary tract cancer, survivorship involves regular monitoring with scans and CA 19-9 blood tests to check for recurrence. Long-term care also focuses on managing potential complications like biliary strictures, nutritional deficiencies, and scanxiety.

Moving from the intensive phase of treatment into survivorship is a major milestone, but it often brings a new set of challenges. Transitioning from frequent doctor visits to a schedule of “watchful waiting” can feel like losing a safety net. Understanding what to expect during this phase can help you regain a sense of control over your health and your life [1].

The Surveillance Roadmap

After curative-intent surgery, your medical team will monitor you closely to catch any potential recurrence as early as possible. While every plan is personalized based on your specific risk factors, a typical schedule looks like this:

  • Years 1–2: This is the highest-risk period for recurrence. You will likely have physical exams, blood work (including CA 19-9), and cross-sectional imaging (CT or MRI) every 3 to 6 months [1][2].
  • Years 3–5: If the cancer has not returned, the frequency usually stretches out to every 6 to 12 months [1].
  • Beyond 5 Years: While some centers stop formal surveillance at five years, many doctors continue annual check-ins, as late complications or recurrences can occasionally occur [1][3].

Monitoring with CA 19-9: Facts and Flaws

CA 19-9 is a protein (tumor marker) often found in the blood of people with biliary tract cancers. While it is a helpful tool, it is not a perfect “cancer detector” [4][5].

  1. Baseline Matters: The most important use of CA 19-9 is comparing your current level to your post-surgery “baseline” [6][7].
  2. The Obstruction Effect: Non-cancerous issues like a blocked bile duct, a stone, or cholangitis (infection) can cause CA 19-9 to skyrocket. An elevated number does not always mean the cancer is back [8][5].
  3. Non-Secretors: About 5–10% of the population lacks the “Lewis antigen” needed to produce CA 19-9. In these patients, the marker will always be low, even if cancer is present. If you are a non-secretor, your doctors will rely entirely on imaging [9][10].

Navigating Long-Term Complications

Even after a successful surgery or the placement of a stent, the biliary system remains sensitive. Two common long-term issues include:

  • Biliary Strictures: These are narrowings that can form where the bile duct was reconstructed (the anastomosis). These can cause bile to back up, leading to jaundice or itching [11][12].
  • Nutritional Changes: Because bile is essential for absorbing fats, surgery can sometimes lead to deficiencies in fat-soluble vitamins (A, D, E, and K). These deficiencies are typically managed with specialized, high-dose supplements prescribed by a clinical dietitian or GI doctor [13].

Managing “Scanxiety” and the Psychological Toll

The “waiting game” of follow-up scans can trigger a unique form of distress often called scanxiety.

  • The Psychological Gap: While research often focuses on physical survival markers like sarcopenia (muscle loss), the emotional reality of living as a survivor is just as significant [13][14].
  • Coping Strategies: Many survivors find it helpful to schedule scans on Mondays so they don’t have to wait through a weekend for results, or to bring a “point person” to appointments to help record information when anxiety makes it hard to focus.

survivorship is a shift in perspective. While you are no longer in “crisis mode,” you are now an active partner in long-term monitoring, ensuring that you and your team are ready for whatever comes next [1][15].

Common questions in this guide

How often will I need scans after biliary cancer surgery?
During the first two years, you will typically have physical exams, blood work, and imaging scans every 3 to 6 months. If the cancer has not returned after that, monitoring usually stretches to every 6 to 12 months.
What does an elevated CA 19-9 level mean during survivorship?
An elevated CA 19-9 does not always mean the cancer has returned. Non-cancerous issues like a blocked bile duct, a stone, or a biliary infection can also cause this tumor marker to rise significantly.
What does it mean to be a CA 19-9 non-secretor?
About 5 to 10 percent of the population lacks the specific antigen needed to produce CA 19-9. If you are a non-secretor, this tumor marker will always appear low even if cancer is present, so your doctors will rely entirely on imaging scans.
Why might my doctor check my vitamin levels after gallbladder surgery?
Because bile is essential for absorbing fats, surgery on your biliary system can lead to deficiencies in fat-soluble vitamins like A, D, E, and K. Your doctor may monitor these levels and prescribe specialized supplements if needed.
What are the signs of a biliary stricture or infection?
A narrowing of the bile duct, called a stricture, can cause bile to back up, leading to jaundice or severe itching. If you experience a sudden fever or chills, you should contact your doctor immediately to rule out a biliary infection.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific surveillance schedule we will follow for the next two years, and which imaging (CT or MRI) do you prefer?
  2. 2.My CA 19-9 is [Number]. Is this considered my baseline, and how do we interpret it if it fluctuates slightly?
  3. 3.Am I a 'Lewis antigen non-secretor'? Does my body actually produce CA 19-9?
  4. 4.Are there specific nutritional markers, like fat-soluble vitamins, that we should be checking regularly since my biliary anatomy has changed?
  5. 5.Who should I call if I experience a sudden fever or chills to rule out a biliary infection?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Evaluation of Tumor Markers and Their Impact on Prognosis in Gallbladder, Bile Duct and Cholangiocellular Carcinomas - A Pilot Study.

    Liska V, Treska V, Skalicky T, et al.

    Anticancer research 2017; (37(4)):2003-2009 doi:10.21873/anticanres.11544.

    PMID: 28373474
  2. 2

    Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach.

    Komaya K, Ebata T, Yokoyama Y, et al.

    Surgery 2018; (163(4)):732-738 doi:10.1016/j.surg.2017.08.011.

    PMID: 29336813
  3. 3

    Common bile duct stone development due to a Hem-o-lok clip migration: a rare complication of laparoscopic cholecystectomy.

    Roh YJ, Kim JW, Jeon TJ, Park JY

    BMJ case reports 2019; (12(7)) doi:10.1136/bcr-2019-230178.

    PMID: 31352393
  4. 4

    Clinical significance of CA 19-9 elevation during postoperative surveillance for extrahepatic bile duct cancer: a nomogram-based approach for the prediction of short-term recurrence.

    Kwon YJ, Min JH, Hwang JA, et al.

    HPB : the official journal of the International Hepato Pancreato Biliary Association 2025; (27(2)):195-205 doi:10.1016/j.hpb.2024.10.015.

    PMID: 39586759
  5. 5

    Carbohydrate Antigen (CA 19-9) Surge: Unraveling the Enigma of Elevated Levels in the Setting of Benign Etiologies.

    Ansari N, Ozgur SS, Besada D, et al.

    Cureus 2024; (16(4)):e57469 doi:10.7759/cureus.57469.

    PMID: 38699139
  6. 6

    Importance of Normalization of Carbohydrate Antigen 19-9 in Patients With Intrahepatic Cholangiocarcinoma.

    Li H, Feng Y, Liu C, et al.

    Frontiers in oncology 2021; (11()):780455 doi:10.3389/fonc.2021.780455.

    PMID: 35004301
  7. 7

    CA 19-9 Surveillance Detects Recurrences Early and Contributes to Improvement in Survival in Resected Ampullary Cancers: Analysis of 572 Cases.

    Bhandare MS, Varty GP, Reddy Obili RC, et al.

    Annals of surgery 2026; (283(2)):286-296 doi:10.1097/SLA.0000000000006419.

    PMID: 38939924
  8. 8

    An Unusual Case of Intrahepatic Stone Masquerading as Cholangiocarcinoma.

    Williams AS, Sikes MA, Liu S

    ACG case reports journal 2025; (12(2)):e01607 doi:10.14309/crj.0000000000001607.

    PMID: 39916889
  9. 9

    KRAS Mutation Allele Frequency Dynamics in Plasma Extracellular Vesicles: Association with Survival in Localized Pancreatic Adenocarcinoma.

    Chopra A, He HZ, Milosevic J, et al.

    Annals of surgical oncology 2026; (33(2)):1605-1615 doi:10.1245/s10434-025-18633-7.

    PMID: 41186643
  10. 10

    Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma.

    Kim SY, Lee HS, Bang SM, et al.

    Cancers 2021; (13(8)) doi:10.3390/cancers13081828.

    PMID: 33921232
  11. 11

    Long-term follow-up and risk factors for strictures after hepaticojejunostomy for bile duct injury: An analysis of surgical and percutaneous treatment in a tertiary center.

    Booij KAC, Coelen RJ, de Reuver PR, et al.

    Surgery 2018; (163(5)):1121-1127 doi:10.1016/j.surg.2018.01.003.

    PMID: 29475612
  12. 12

    Open injury, robotic repair-moving ahead! Total robotic Roux-en-Y hepaticojejunostomy for post-open cholecystectomy Bismuth type 2 biliary stricture using indocyanine green dye.

    Rathore KS, Varshney P, Soni SC, et al.

    Journal of minimally invasive surgery 2023; (26(3)):151-154 doi:10.7602/jmis.2023.26.3.151.

    PMID: 37712315
  13. 13

    Preoperative Myosteatosis and Prognostic Nutritional Index Predict Survival in Older Patients With Resected Biliary Tract Cancer.

    Utsumi M, Inagaki M, Kitada K, et al.

    Cancer diagnosis & prognosis 2024; (4(2)):147-156 doi:10.21873/cdp.10301.

    PMID: 38434914
  14. 14

    Biliary tract cancer.

    Valle JW, Kelley RK, Nervi B, et al.

    Lancet (London, England) 2021; (397(10272)):428-444 doi:10.1016/S0140-6736(21)00153-7.

    PMID: 33516341
  15. 15

    Conditional Recurrence-Free Survival for Patients with Gallbladder Cancer: A Personalized Resource for Patients and Providers.

    Ejaz A, Pawlik TM

    Annals of surgical oncology 2021; (28(5)):2436-2437 doi:10.1245/s10434-021-09629-0.

    PMID: 33528709

This page provides general information about gallbladder and biliary tract cancer survivorship. It is for educational purposes only and should not replace personalized advice from your oncology team.

Get notified when new evidence is published on Carcinoma of gallbladder and extrahepatic biliary tract.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.